Applying pharmacodynamics for susceptibility breakpoint selection and susceptibility testing

Antimicrobial Pharmacodynamics in Theory and Clinical Practice, Second Edition

Volumn , Issue , 2007, Pages 21-44

  Mouton, Johan W ^a   Ambrose, Paul G ^b   Kahlmeter, Gunnar ^c   Wikler, Matt ^d   Craig, William A ^e  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c CENTRAL HOSPITAL   (Sweden)

^d Pacific Beach BioSciences   (United States)

^e WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955396763     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Drusano GL, D'Argenio DZ, Preston SL, et al. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother 2000; 44(6):1655-1659.
2. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001; 45(1):13-22.
3. Kahlmeter G, Brown DFJ, Goldstein FW, et al. European harmonisation of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrobial Chemotherapy 2003; 52(2):145-148.
4. NCCLS. Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline-Second Edition. NCCLS document M23-A2. Wayne: NCCLS, 2001.
5. Ericsson HM, Sherris JC. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1971; 217(suppl B):1-90.
6. Soussy CJ, Cluzel R, Courvalin P. Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. The Comite de l'Antibiogramme de la Societe Francaise de Microbiologie. Eur J Clin Microbiol Infect Dis 1994; 13(3):238-246.
7. MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001; 48(suppl 1):17-28.
8. Mouton JW, van Klingeren B, de Neeling AJ, Degener JE, Commissie Richtlijnen Gevoeligheidsbepalingen. Het vaststellen van gevoeligheidskriteria voor antibacteriele middelen in Nederland: verleden, heden en toekomst. Nederlands Tijdschrift voor Med Microbiol 2000; 8(3):73-78.
9. Swedish Reference Group of Antibiotics. Antimicrobial susceptibility testing in Sweden. Scandinav J Infect Dis 1997; 105S:5-31.
10. Bergan T, Bruun JN, Digranes A, Lingaas E, Melby KK, Sander J. Susceptibility testing of bacteria and fungi. Report from "the Norwegian Working Group on Antibiotics". Scand J Infect Dis Suppl 1997; 103:1-36.
11. Deutsches Institut fur Normung. DIN 58 940-10, Criteria for the Categorization of the In-Vitro Activity of Antimicrobial Agents. Beuth Verlag: Deutsches Institut fur Normung, 1990.
12. Kahlmeter G, Brown DF, Goldstein FW, et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 2006; 12(6):501-503.
13. Website www.eucast.org
14. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108(5 Pt 2): 835-840.
15. Shah PM, Junghanns, Stille W. Bactericidal dosie-activity relationships with E. coli, K. pneumoniae and Staph. aureus (author's transl.). Dtsch Med Wochenschr 1976; 101(9):325-328.
16. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26(1):1-10; quiz 11-2.
17. Scaglione F, Mouton JW, Mattina R. Pharmacodynamics of levofloxacin in a murine pneumonia model: importance of peak to MIC ratio versus AUC. Interscience Conference Antimicrobial Agents Chemotherapy, 1999. San Francisco: American Society Microbiology, 1999:6.
18. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquino-lone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40(3):627-632.
19. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43(1):79-86.
20. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciproflox-acin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999; 43(3):672-677.
21. Lister PD, Sanders CC. Pharmacodynamics of trovafloxacin, of loxacin, and ciproflox-acin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1999; 43(5):1118-1123.
22. Lister PD. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Antimicrob Agents Chemother 2002; 46(1):69-74.
23. Fernandez J, Barrett JF, Licata L, Amaratunga D, Frosco M. Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess. Antimicrob Agents Chemother 1999; 43(3):667-671.
24. Ng W, Lutsar I, Wubbel L, et al. Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin- resistant Streptococcus pneumoniae pneumonia. J Antimicrob Chemother 1999; 43(6):811-816.
25. Onyeji CO, Bui KQ, Owens RC Jr, Nicolau DP, Quintiliani R, Nightingale CH. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int J Antimicrob Agents 1999; 12(2):107-114.
26. Bedos JP, Rieux V, Bauchet J, Muffat-Joly M, Carbon C, Azoulay-Dupuis E. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother 1998; 42(4):862-867.
27. Bedos JP, Azoulay-Dupuis E, Moine P, et al. Pharmacodynamic activities of ciproflox-acin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. J Pharmacol Exp Ther 1998; 286(1):29-35.
28. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroqui-nolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37(3):483-490.
29. Andes DR, Craig WA. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis 1998; 27(1):47-50.
30. Ernst EJ, Klepser ME, Petzold CR, Doern GV. Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. Pharmacotherapy 2002; 22(4):463-470.
31. Croisier D, Chavanet P, Lequeu C, et al. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 2002; 50(3):349-360.
32. Mattoes HM, Banevicius M, Li D, et al. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45(7):2092-2097.
33. Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40(suppl A):45-57.
34. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacody-namics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37(5):1073-1081.
35. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials (see comments). J Am Med Assoc 1998; 279(2):125-129.
36. Highet VS, Forrest A, Ballow CH, Schentag JJ. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 1999; 43(suppl A):55-63.
37. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacody-namics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45(10):2793-2797.
38. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31(7):1054-1060.
39. Mouton JW. Breakpoints: current practice and future perspectives. Int J Antimicrob Agents 2002; 19(4):323-331.
40. Mouton JW. Het gebruik van farmcodynamische parameters voor het vaststellen van gevoeligheidscriteria van fluorchinolonen. Nederlands Tijdschrift voor Med Microbiol 2000; 8(3):82-86.
41. Mouton JW. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 2003; 17(3):579-598.
42. Cars O. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand J Infect Dis Suppl 1990; 74:23-33.
43. Liu P, Muller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations vs. tissue concentrations. Int J Antimicrob Agents 2002; 19(4): 285-290.
44. NCCLS. Performance Standards for Antimicrobial Susceptibility Testing; 10th International Supplement. M100-S10 (M7). Wayne: NCCLS, 2000.
45. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42(9):2375-2379.
46. Tompsett R, Shultz S, McDermott W. The relation of protein binding to the pharmacology and antibacterial activity of penicillins X, G, dhydro F, and K. J Bacteriol 1947; 53:581-595.
47. Kunin CM, Craig WA, Kornguth M, Monson R. Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci 1973; 226:214-224.
48. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22(1-2):89-96.
49. Ryan DM, Cars O. Antibiotic assays in muscle: are conventional tissue levels misleading as indicator of the antibacterial activity? Scand J Infect Dis 1980; 12(4):307-309.
50. Ryan DM, Cars O. A problem in the interpretation of beta-lactam antibiotic levels in tissues. J Antimicrob Chemother 1983; 12(3):281-284.
51. Bergan T, Engeset A, Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics? Rev Infect Dis 1987; 9(4):713-718.
52. Craig WA, Suh B. Theory and practical impact of binding of antimicrobials to serum proteins and tissue. Scand J Infect Dis Suppl 1978; 14:92-99.
53. Drusano GL, Preston SL, Gotfried MH, Danziger LH, Rodvold KA. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation. Antimicrob Agents Chemother 2002; 46(2):586-589.
54. Mouton JW, Horrevorts AM, Mulder PG, Prens EP, Michel MF. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 1990; 34(12):2307-2311.
55. Wise R, Baker S, Livingston R. Comparison of cefotaxime and moxalactam pharmaco-kinetics and tissue levels. Antimicrob Agents Chemother 1980; 18(3):369-371.
56. Muller M, Haag O, Burgdorff T, et al. Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob Agents Chemother 1996; 40(12):2703-2709.
57. Marchand S, Chenel M, Lamarche I, Couet W. Pharmacokinetic modeling of free amoxicillin concentrations in rat muscle extracellular fluids determined by microdialysis. Antimicrob Agents Chemother 2005; 49(9):3702-3706.
58. Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006; 50(7):2455-2463.
59. Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Comparative intracel-lular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother 2002; 46(7):2095-2103.
60. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48(suppl 1):5-16.
61. EUCAST. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Discussion Document E. Dis 5.1. Munich, Germany: European Society Clinical Microbiology and Infectious Diseases, 2003.
62. Bonate PL. A brief introduction to Monte Carlo simulation. Clin pharmacokinetic 2001; 40:15-22.
63. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmaco-dynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 38(3):151-157.
64. Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med 2001; 111(suppl 9A):13S-18S; discussion 36S-38S.
65. Montgomery MJ, Beringer PM, Aminimanizani A, et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45(12):3468-3473.
66. Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC. Monte Carlo predictions of dosage regimens for BAL5788, a new broad-spectrum cephalosporin active against MRSA. Interscience Conference Antimicrobial Agents Chemotherapy, 2002. San Diego: American Society Microbiology, 2002.
67. Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005; 27(6):762-772.
68. Ambrose PG. Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints. Treat Respir Med 2005; 4(suppl 1):5-11.
69. Ambrose PG. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2006; 26(1):129-134.
70. Ambrose PG, Bhavnani SM, Jones RN, Craig WA. Use of Pharmacokinetics-pharmaco-dynamics and Monte-Carlo simulation as decision support for the reevaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae. 44th Interscience Conference Antimicrobial Agents and Chemotherapy; Oct 12th-Nov 2nd, 2004, Washington, D.C.: ASM, 2004:12.
71. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43(10):1116-1123.
72. Stearne LE, Gyssens IC, Goessens WH, et al. In vivo efficacy of trovafloxacin against bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. Anti-microb Agents Chemother 2001; 45(5):1394-1401.
73. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112(2):275-285.
74. Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale CH, Murakawa T, Ambrose PG, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel Dekker, Inc., 2002.
75. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44(1):79-86.
76. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylo-cocci. J Antimicrob Chemother 2002; 50(6):915-932.